Medicenna Therapeutics appoints Jeff Caravella as CFO

Medicenna Therapeutics (MDNA) announced the appointment of Jeff Caravella as CFO. In this position, Caravella will lead Medicenna’s financial strategy to support the Company’s growth. This appointment underscores the Company’s commitment to expanding its operations in Boston and follows the recent appointment of Brent Meadows as Chief Business Officer. Caravella brings to Medicenna over 20 years of global healthcare, financial and operational experience. Most recently, he served as CFO at Biotheryx, where he led the finance, investor relations and operational functions and supported activities associated with an up to approximately $350M collaboration with Incyte. Prior to Biotheryx, he served as Vice President of Finance at Tango Therapeutics (TNGX), where he built and led the finance and accounting functions, successfully supported approximately $110M in private financings and an approximately $350M SPAC and PIPE transaction. Previously, Jeff held senior finance roles at Editas Medicine (EDIT), Charles River Laboratories and Johnson & Johnson (JNJ).